Zensun Completed Chinese Phase II Clinical Study of rhNRG-1

Zensun accomplished Chinese phase II clinical trial of rhNRG-1—Zensun’s proprietary anti-heart failure drug. During the past two years, Zensun conducted randomized, double-Blind, multi-center, placebo-controlled phase II clinical studies in over 30 hospitals nationwide. The initial statistics show that the heart function was improved effectively with rhNRG-1 treatment. In May 21st, 2009, Zensun held press conference in Zhangjiang, Shanghai and claimed phase II clinical study report in China and Australia to the media worldwide.

The release as fetched from its publisher. zensun.com ↗